Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

March 15, 2013

Primary Completion Date

March 3, 2017

Study Completion Date

November 7, 2017

Conditions
FAPFamilial Amyloid PolyneuropathyTTRTransthyretinAmyloidosis
Interventions
DRUG

Inotersen

DRUG

Placebo

Trial Locations (24)

10029

Mount Sinai Medical Center, New York

10032

Columbia University Medical Center - The Neurological Institute, New York

19104

Penn Presbyterian Medical Center, Philadelphia

21205

Johns Hopkins University Bayview Medical Center, Baltimore

27100

Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico San Matteo, Pavia

46202

Indiana University School of Medicine, Indianapolis

48149

UKM; Universitätsklinikum Münster, Klinik für Transplantationsmedizin, Münster

55905

Mayo Clinic, Rochester

92868

University of California, Irvine, Orange

94000

CHU Henri Mondor - Department of Neurology, Créteil

94275

CHU Bicetre Aphp French Referral Center for FAP/Cornamyl Network, Le Kremlin-Bicêtre

97239

Oregon Health & Science University, Portland

98124

"Universita Degli Studi Di Messina - Azienda Ospedaliera Universitaria Policlinico Gaetano Martino", Messina

02118

Boston University School of Medicine - Amyloid Treatment & Research Program, Boston

Unknown

FLENI, Buenos Aires

AACD, São Paulo

UNIFESP, São Paulo

Auckland City Hospital, Auckland

CEP 21941913

Federal University of Rio de Janeiro - University Hospital, Rio de Janeiro

1649-035

CHLN - Hospital de Santa Maria, Lisbon

4099-001

CHP-HGSA, Unidade Clinica de Paramiloidose, Porto

08035

Hospital Universitari Vall D' Hebron, Barcelona

08036

Hospital Clínic, Barcelona

NW3 2PF

University College London - National Amyloidosis Centre, London

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY